Erythropoietin Human Recombinant
Pulmonary Hypertension
National Heart, Lung, and Blood Institute (NHLBI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Pulmonary Hypertension cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sildenafil Duke University | Phase 4 | BB |
Epoprostenol National Center for Research Resources (NCRR) | Phase 4 | BB |
Tadalafil Ochsner Health System | Phase 4 | B |
Tadalafil Ochsner Health System | Phase 4 | B |
ut-15 United Therapeutics | Phase 3 | B |
View all 31 →
Same molecule, other indications
Erythropoietin Human Recombinant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →